SyntheX (Drug Discovery) Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 14

SyntheX (Drug Discovery) General Information

Description

Developer of a proprietary drug discovery platform designed to find protein interaction disruptors, bridgers, and molecular glue degraders. The company utilizes genetically engineered circuits, technologies, and proprietary DNA-encoded peptide and macrocycle libraries that rely on intracellular drug selection as opposed to in vitro screening, enabling healthcare institutions to serve human health for the treatment of cancer and rare diseases.

Contact Information

Website
synthexlabs.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 455 Mission Bay Boulevard South
  • Suite 145
  • San Francisco, CA 94158
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Automation/Workflow Software
Corporate Office
  • 455 Mission Bay Boulevard South
  • Suite 145
  • San Francisco, CA 94158
  • United States
+1 (415)

SyntheX (Drug Discovery) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SyntheX (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A) 23-May-2025 Completed Pre-Clinical Trials
7. Accelerator/Incubator 10-Oct-2024 Completed Pre-Clinical Trials
6. Seed Round 10-Jan-2024 Completed Pre-Clinical Trials
5. Debt - PPP 27-Apr-2020 Completed Pre-Clinical Trials
4. Accelerator/Incubator 28-Jan-2019 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Jan-2019 Completed Pre-Clinical Trials
2. Seed Round 27-Apr-2017 $6.15M $6.4M Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Mar-2016 $250K $250K Completed Product In Beta Test
To view SyntheX (Drug Discovery)’s complete valuation and funding history, request access »

SyntheX (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view SyntheX (Drug Discovery)’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SyntheX (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a proprietary drug discovery platform designed to find protein interaction disruptors, bridgers, and molecu
Drug Discovery
San Francisco, CA
40 As of 2026

Cambridge, United Kingdom
 

Vienna, Austria
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SyntheX (Drug Discovery) Competitors (10)

One of SyntheX (Drug Discovery)’s 10 competitors is PhoreMost, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PhoreMost Venture Capital-Backed Cambridge, United Kingdom
Proxygen Venture Capital-Backed Vienna, Austria
Cullgen Formerly VC-backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
Vividion Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 10 competitors. Get the full list »

SyntheX (Drug Discovery) Patents

SyntheX (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020275425-A1 Selective degradation of proteins Active 15-May-2019
AU-2020275425-B2 Selective degradation of proteins Active 15-May-2019
AU-2024219968-A1 Selective degradation of proteins Pending 15-May-2019
EP-3969592-A4 Selective degradation of proteins Pending 15-May-2019
JP-2024019600-A Selective degradation of proteins Pending 15-May-2019 C40B40/02
To view SyntheX (Drug Discovery)’s complete patent history, request access »

SyntheX (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SyntheX (Drug Discovery) Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Merck Digital Sciences Studio Accelerator/Incubator Minority
The Column Group Venture Capital Minority
Endless Frontier Labs Accelerator/Incubator Minority
OMX Ventures Venture Capital Minority
MBC BioLabs Accelerator/Incubator Minority
You’re viewing 5 of 14 investors. Get the full list »

SyntheX (Drug Discovery) FAQs

  • When was SyntheX (Drug Discovery) founded?

    SyntheX (Drug Discovery) was founded in 2016.

  • Where is SyntheX (Drug Discovery) headquartered?

    SyntheX (Drug Discovery) is headquartered in San Francisco, CA.

  • What is the size of SyntheX (Drug Discovery)?

    SyntheX (Drug Discovery) has 40 total employees.

  • What industry is SyntheX (Drug Discovery) in?

    SyntheX (Drug Discovery)’s primary industry is Drug Discovery.

  • Is SyntheX (Drug Discovery) a private or public company?

    SyntheX (Drug Discovery) is a Private company.

  • What is SyntheX (Drug Discovery)’s current revenue?

    The current revenue for SyntheX (Drug Discovery) is .

  • How much funding has SyntheX (Drug Discovery) raised over time?

    SyntheX (Drug Discovery) has raised $11.6M.

  • Who are SyntheX (Drug Discovery)’s investors?

    Merck Digital Sciences Studio, The Column Group, Endless Frontier Labs, OMX Ventures, and MBC BioLabs are 5 of 14 investors who have invested in SyntheX (Drug Discovery).

  • Who are SyntheX (Drug Discovery)’s competitors?

    PhoreMost, Proxygen, Cullgen, Arvinas, and Vividion Therapeutics are some of the 10 competitors of SyntheX (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process